GAITHERSBURG, Md., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and six months ended June 30, 2017.
Q2 2017 AND RECENT BUSINESS ACCOMPLISHMENTS
•Signed an agreement with Sanofi to acquire their ACAM2000® smallpox business, including:
